BioSpace News Archive

AZEDRA is not approved for use outside of the United States.

Biofidelity Ltd, a company providing advanced molecular assays for the sensitive detection of low-frequency genetic mutations, today announces it has received £500,000 in grant funding from Innovate UK, the UK’s Innovation Agency.

Minimally invasive carotid artery disease treatment reduces stroke risk

Zymergen Signing Reinforces BioMed Realty’s Growth in the San Francisco Bay Area

Ferring Pharmaceuticals (US) today announced that it will be presenting five company-sponsored abstracts at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo taking place on October 12-16, 2019, in Philadelphia, Pennsylvania.

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced the promotion of Chief Operating Officer Ari Hoffnung to the newly created role of Chief Strategy Officer.

There is nearly a 40% chance of overdiagnosing chronic obstructive pulmonary disease (COPD) when spirometry is not combined with bronchodilator (BD) testing, often missing asthma and asthma-COPD overlap syndrome (ACOS), according to Srinadh Annangi, MD, from the University of Kentucky, School of Medicine, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans

Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to Kam Sing Ho, MD, from Mount Sinai St. Luke’s and Mount Sinai West in New York City, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.

INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility & developers of INVOcell®, the first FDA-cleared Intravaginal Culture System, today announced the appointment of Steven Shum as the Company’s Chief Executive Officer, effective immediately

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding